Evolus (EVL) Price & Analysis

4 Followers

EVL Stock Chart & Stats

€7.62

-€0.05(-0.91%)

At close: Jul 24 4:00 PM EDT

€7.62

-€0.05(-0.91%)

Day’s Range― - ―

52-Week Range€3.42 - €7.93

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€433.04M

Enterprise Value€577.18M

Total Cash (Recent Filing)€45.17M

Total Debt (Recent Filing)€164.80M

Price to Earnings (P/E)―

Beta0.44

Next Earnings

Nov 10, 2026

EPS Estimate

-0.06

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.52

Shares Outstanding66,050,440

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio6.73

Price to Book (P/B)-18.55

Price to Sales (P/S)1.44

P/FCF Ratio-8.45

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€12.79

Price Target Upside67.85% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

EPS Forecast (FY)-0.04

Revenue Forecast (FY)€297.87M

Bulls Say, Bears Say

Bulls Say

Revenue Growth And Gross MarginDouble-digit revenue growth combined with gross margins near 67% indicates strong product economics and continued commercial traction. If sustained, this mix can provide operating leverage as Evolus scales its portfolio, supports reinvestment, and moves toward durable profitability.

Broader Product PortfolioExpansion beyond Jeuveau into Evolysse, Estyme, and international markets broadens the company’s addressable opportunity and gives providers more reasons to buy across products. Multi-product adoption can deepen account relationships and reduce dependence on a single offering over time.

Improving Adjusted EBITDAThree consecutive quarters of positive adjusted EBITDA suggest the commercial model is progressing beyond revenue growth toward better operating efficiency. Continued profitability at the adjusted level would improve internal funding capacity and strengthen confidence in the company’s longer-term earnings trajectory.

Bears Say

FDA Promotional ComplianceThe FDA’s warning creates a durable compliance and reputational concern around promotion of Jeuveau, the company’s core product. Required changes to marketing practices could constrain commercial messaging, while further scrutiny could increase regulatory costs and affect provider confidence.

Leveraged, Negative-Equity Balance SheetRising debt alongside negative equity leaves Evolus with limited financial flexibility while it works toward sustained profitability. This capital structure can restrict investment choices, increase dependence on financing facilities, and make the business more vulnerable if growth or earnings improvement slows.

Persistent Cash BurnNegative operating and free cash flow show that reported growth and narrowing losses have not yet translated into self-funding operations. Continued cash consumption may require reliance on available facilities, limiting the resources available for product launches, expansion, and balance-sheet repair.

Evolus News

Evolus enters option agreement with privately held company

Evolus (EOLS) announced that it has entered into an option agreement with a privately held company developing a...

7d ago

EOLS

FDA sends letter to Evolus over ‘misleading’ Jeuveau ad

The FDA posted a letter sent to Evolus (EOLS) regarding the company’s promotional communication for Jeuveau. The FDA...

19d ago

EOLS

Evolus falls 5% to $7.12 after FDA send letter over marketing

10:19 EDT Evolus (EOLS) falls 5% to $7.12 after FDA send letter over marketing Published first on TheFly...

19d ago

EOLS

Evolus launches Wings by Evolus charitable platform

Evolus (EOLS) announced the launch of Wings by Evolus, a new charitable platform designed to bring together aesthetic...

20d ago

EOLS

Evolus weakness a buying opportunity, says Mizuho

Mizuho notes that Evolus (EOLS) shares were down 8% today and believes the relative underperformance is likely macro-driven...

1M ago

EOLS

Telix names David Gill chair of the board

Telix Pharmaceuticals (TLX) announced that David Gill has been appointed Chair of the Board, effective immediately. Gill joined...

2M ago

EOLS

Evolus: Buy Rating Reiterated on Strong Execution, Raised Guidance and Unchanged $13 Price Target

Analyst Sam Eiber from BTIG reiterated a Buy rating on Evolus and keeping the price target at $13.00....

3M ago

EOLS

Evolus Inc. Earnings Call Signals Confident Growth

Evolus, Inc. (($EOLS)) has held its Q2 earnings call. Read on for the main highlights of the call....

3M ago

EOLS

Evolus reports Q2 EPS (12c), consensus (4c)

Reports Q2 revenue $84.1M, consensus $81.54M. “The increasing momentum of our portfolio focus has resulted in Evolus (EOLS)...

3M ago

EOLS

Evolus raises FY26 revenue view to $330M-$337M from $327M-$337M

Consensus $330.45M. Raises adjusted gross profit margin for the full-year 2026 to between 67.0% and 67.5%, from 65.5%...

3M ago

EOLS

Evolus Expands Estyme Aesthetic Portfolio into New Markets

The latest update is out from Evolus ( ($EOLS) ). On August 3, 2026, Evolus Pharma B.V., a...

3M ago

EOLS

Evolus expands strategic partnership with Symatese to commercialize Estyme

Evolus (EOLS) announced it has expanded its partnership with Symatese through an amendment to the companies’ existing licensing...

3M ago

EOLS

Evolus Secures U.S. Profhilo Distribution Agreement

Evolus ( ($EOLS) ) has provided an announcement. On July 7, 2026, Evolus entered an exclusive U.S. license,...

3M ago

EOLS

Evolus partners with IBSA to develop and market Profhilo in the U.S.

Evolus (EOLS) has entered into an exclusive licensing and distribution agreement with IBSA, a Swiss multinational pharmaceutical company,...

3M ago

EOLS

EVL FAQ

What was Evolus Inc’s price range in the past 12 months?

Evolus Inc lowest stock price was €3.42 and its highest was €7.93 in the past 12 months.

What is Evolus Inc’s market cap?

Evolus Inc’s market cap is €433.04M.

When is Evolus Inc’s upcoming earnings report date?

Evolus Inc’s upcoming earnings report date is Nov 10, 2026 which is in 20 days.

How were Evolus Inc’s earnings last quarter?

Evolus Inc released its earnings results on Aug 05, 2026. The company reported €0.006 earnings per share for the quarter, beating the consensus estimate of -€0.029 by €0.036.

Is Evolus Inc overvalued?

According to Wall Street analysts Evolus Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Evolus Inc pay dividends?

Evolus Inc does not currently pay dividends.

What is Evolus Inc’s EPS estimate?

Evolus Inc’s EPS estimate is -0.06.

How many shares outstanding does Evolus Inc have?

Evolus Inc has 66,050,440 shares outstanding.

What happened to Evolus Inc’s price movement after its last earnings report?

Evolus Inc reported an EPS of €0.006 in its last earnings report, beating expectations of -€0.029. Following the earnings report the stock price went up 5.301%.

Which hedge fund is a major shareholder of Evolus Inc?

Currently, no hedge funds are holding shares in DE:EVL

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Evolus Stock Smart Score

Outperform

Fundamentals

Return on Equity

123.11%

Trailing 12-Months

Asset Growth

8.40%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Evolus Inc

Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation. This product is specifically designed for adults seeking the temporary smoothing of moderate to severe glabellar (frown) lines. Founded in 2012, Evolus, Inc. maintains its corporate headquarters in Newport Beach, California.

Evolus (EVL) Earnings & Revenues

Historic Earnings Reports

EVL Company Deck

EVL Earnings Call

Q2 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call communicated clear operational momentum: double-digit top-line growth (21% in Q2, 14% year-to-date), third consecutive quarter of positive adjusted EBITDA, expanded international presence, new strategic licensing (ProFuelo) and an upwardly revised full-year revenue and margin outlook. These positives were tempered by sequential increases in operating expenses, modest absolute adjusted EBITDA, a decline in cash versus the prior quarter and ongoing tariff uncertainty that requires inventory repositioning. Given the company’s raised guidance, profitable growth trajectory, and strategic partnerships that expand the product portfolio, the highlights materially outweigh the lowlights.View all DE:EVL earnings summaries

EVL Stock 12 Month Forecast

Average Price Target

€12.79

▲(67.85% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"€2","9":"€9","16":"€16","5.5":"€5.5","12.5":"€12.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":15.16944272,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€15.17</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12.789922293333333,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€12.79</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11.60016208,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€11.60</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,5.5,9,12.5,16],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.056,7.6801109784615385,8.304221956923076,8.928332935384615,9.552443913846153,10.176554892307692,10.80066587076923,11.424776849230767,12.048887827692306,12.672998806153846,13.297109784615383,13.92122076307692,14.545331741538458,{"y":15.16944272,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.056,7.497070945641026,7.938141891282052,8.379212836923077,8.820283782564102,9.261354728205129,9.702425673846154,10.14349661948718,10.584567565128205,11.02563851076923,11.466709456410257,11.907780402051284,12.348851347692307,{"y":12.789922293333333,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.056,7.4055509292307695,7.755101858461538,8.104652787692308,8.454203716923077,8.803754646153847,9.153305575384616,9.502856504615384,9.852407433846153,10.201958363076923,10.551509292307692,10.901060221538462,11.250611150769231,{"y":11.60016208,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.35,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.75,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.05,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.6,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.02,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.66,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.52,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.392,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.592,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.018,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.19,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.77,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.056,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >